The U.S. Food and Drug Administration (FDA) recently released draft guidance on the protocol for cosmetic product facility registrations and product listings, in compliance with the requirements of the Modernization of Cosmetics Regulation Act of 2022 (MoCRA).
This newly issued guidance will have a significant impact on the global cosmetics industry, altering the usual practices of cosmetic product facilities and production sites. It is noted that this regulation not only affects domestic industry players, but international parties interested in the U.S. market need to keep a close eye on these changes that MoCRA has instated.
Prior to the implementation of MoCRA, the protocol related to registration and listing of cosmetic facilities had different restrictions and compliance requirements. This new draft guidance indicates a major shift in policy, ensuring stricter regulations, increased transparency and improved tracking of cosmetic products.
The guidance is still under review and stakeholders in the cosmetic industry have the opportunity to offer their comments and feedback to the FDA. The agency’s deliberate approach to stakeholder consultation is aimed at allowing all parties impacted by this rule to provide input before the final rule is officially put into place.
The draft guidance is available for public review and comment. Legal professionals, particularly those in the cosmetics industry, should thoroughly review the guidance to understand the new requirements. Having a deep understanding of the new regulations will be crucial for successful compliance in this new era of cosmetics regulation.
For a comprehensive reading on this subject, you can go through the detailed article published on JD Supra, written by “Shook, Hardy & Bacon L.L.P.”, a reputed law firm with expertise in FDA regulations.